These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 25676036

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy.
    Leitch HA, Chase JM, Goodman TA, Ezzat H, Rollins MD, Wong DH, Badawi M, Leger CS, Ramadan KM, Barnett MJ, Foltz LM, Vickars LM.
    Hematol Oncol; 2010 Mar; 28(1):40-8. PubMed ID: 19557769
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload.
    Payne KA, Rofail D, Baladi JF, Viala M, Abetz L, Desrosiers MP, Lordan N, Ishak K, Proskorovsky I.
    Adv Ther; 2008 Aug; 25(8):725-42. PubMed ID: 18704280
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Predicted costs of iron-chelators in myelodysplastic syndromes: a 10-year analysis based on actual prevalence and red cell transfusion rates.
    Durairaj S, Chew S, Hyslop A, Keenan N, Groves MJ, Tauro S.
    Am J Hematol; 2011 May; 86(5):406-10. PubMed ID: 21523799
    [Abstract] [Full Text] [Related]

  • 10. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE, Hagiwara M, Thomas SK, Baladi JF, Phatak PD, Coates TD.
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Improving erythropoiesis: a compelling case for iron chelation in myelofibrosis.
    Pullarkat V.
    Eur J Haematol; 2016 Jun; 96(6):549-50. PubMed ID: 26572646
    [No Abstract] [Full Text] [Related]

  • 13. Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need.
    Goldberg SL, Chen E, Sasane M, Paley C, Guo A, Laouri M.
    Transfusion; 2012 Oct; 52(10):2131-8. PubMed ID: 22486790
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?
    Wong SA, Leitch HA.
    Leuk Res; 2018 Jan; 64():24-29. PubMed ID: 29149650
    [Abstract] [Full Text] [Related]

  • 16. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
    Delea TE, Edelsberg J, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD.
    Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Increased incidence of infection in patients with myelofibrosis and transfusion-associated iron overload in the clinical setting.
    Caocci G, Simula MP, Ghiani S, Mulas O, Mainas G, Atzeni S, Pettinau M, Usala E, La Nasa G.
    Int J Hematol; 2020 May; 111(5):614-618. PubMed ID: 32207052
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.